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Abstract
Oxygen-dependent regulation of the erythropoietin gene is mediated by the
hypoxia-inducible factor (HIF) family of transcription factors. When oxygen
is plentiful, HIF undergoes hydroxylation by a family of oxygen-dependent
prolyl hydroxylase domain (PHD) proteins, promoting its association with the
von Hippel-Lindau (VHL) ubiquitin E3 ligase and subsequent proteosomal
degradation. When oxygen is scarce, the PHD enzymes are inactivated, leading
to HIF accumulation and upregulation not only of erythropoietin expression,
but also the expression of hundreds of other genes, including those coordinat-
ing cardiovascular and ventilatory adaptation to hypoxia. Nevertheless, despite
the identification of over 50 mutations in the PHD-HIF-VHL pathway in
patients with previously unexplained congenital erythrocytosis, there are very
few reports of associated cardiopulmonary abnormalities. We now report
exaggerated pulmonary vascular and ventilatory responses to acute hypoxia in
a 35-year-old man with erythrocytosis secondary to heterozygous mutation in
PHD2, the most abundant of the PHD isoforms. We compare this phenotype
with that reported in patients with the archetypal disorder of cellular oxygen
sensing, Chuvash polycythemia, and discuss the possible clinical implications
of our findings, particularly in the light of the emerging role for small mole-
cule PHD inhibitors in clinical practice.
Introduction
Oxygen-dependent gene expression is exemplified by ery-
thropoietin (EPO) production, which is mediated by the
hypoxia-inducible factor (HIF) family of transcription fac-
tors (Wang and Semenza 1993; Wang et al. 1995). The
HIF transcriptional complex is a heterodimer comprising a
and b subunits, the former of which is regulated by oxygen
availability mainly through the action of a family of 2-oxo-
glutarate-dependent prolyl hydroxylase domain (PHD)
proteins (Epstein et al. 2001). When oxygen is plentiful,
hydroxylation of two specific proline residues in the HIFa
protein promotes its association with the von Hippel-
Lindau (VHL) ubiquitin E3 ligase, leading to its degrada-
tion in the ubiquitin-proteosomal pathway. When oxygen
is scarce, the PHD enzymes are inactivated, leading to
HIFa accumulation and formation of the transcriptional
complex through binding to nuclear HIFb (Ivan et al.
2001; Jaakkola et al. 2001). Human HIFa exists as three
isoforms (HIF1a, 2a and 3a), which regulate overlapping
sets of genes (Schodel et al. 2011). Similarly, three PHD
isoforms have been described (PHD1, 2 and 3), of which
PHD2 is the most abundant (Appelhoff et al. 2004).
Since the elucidation of the PHD-HIF-VHL pathway,
mutations in its constituent proteins have been identified
in previously unexplained cases of congenital
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erythrocytosis. Chuvash polycythemia, for example, is
endemic in the Upper Volga region of Russia, with spo-
radic cases reported elsewhere, and is characterized by sev-
ere erythrocytosis. It is now known to be due to a
homozygous loss-of-function mutation (598C>T) in the
VHL gene, leading to inappropriate HIFa stabilization,
activation of HIF-mediated gene transcription and EPO
upregulation (Ang et al. 2002). Importantly, this condition
highlights the importance of HIF signaling not only for
EPO regulation, but also in the regulation of systemic oxy-
gen delivery more broadly. Patients with Chuvash poly-
cythemia display elevated minute ventilation and
pulmonary artery pressures at baseline, and profoundly
enhanced pulmonary vascular, ventilatory and cardiac
responses to acute hypoxia (Bushuev et al. 2006; Smith
et al. 2006, 2008b), a phenotype reminiscent of that seen in
lowlanders acclimatized to the hypoxia of high altitude.
To date, over 50 oxygen sensing mutations have been
identified in patients with congenital erythrocytosis
(Bento et al. 2014; Camps et al. 2016; McMullin 2016).
The majority are loss-of-function mutations in VHL or
EGLN1 (PHD2), but gain-of-function mutations in the
EPAS1 (HIF2a) gene have also been described. Cardiopul-
monary abnormalities have been reported in Chuvash
polycythemia, in two infants with distinct VHL mutations
(Bond et al. 2011; Sarangi et al. 2014), and in a small
number of patients with HIF2a mutations (Gale et al.
2008; Formenti et al. 2011). Abnormal cardiopulmonary
physiology associated with PHD2 deficiency has also been
demonstrated in mice (Bishop et al. 2013; Dai et al. 2016;
Hodson et al. 2016; Kapitsinou et al. 2016), but to the
best of our knowledge there are no reports of an analo-
gous cardiopulmonary phenotype in PHD-deficient
humans. We now report exaggerated ventilatory and pul-
monary vascular responses to hypoxia in a patient with
heterozygous PHD2 mutation.
Case Report
We assessed the cardiopulmonary phenotype of a
35-year-old man who had been diagnosed with poly-
cythemia 6 years earlier, with peak hemoglobin and hema-
tocrit of 191 g/L and 0.54, respectively. As reported
previously (Percy et al. 2006), serum EPO was normal
despite the elevated hemoglobin, suggesting dysregulation
of erythropoietin secretion. Following extensive investiga-
tion, this was attributed to heterozygosity for a 950C>G
mutation in the PHD2 gene, corresponding to a proline-
arginine substitution. In vitro, the mutated PHD protein
was less effective at binding and hydroxylating HIF1a and
HIF2a, and in cell culture overexpression of mutant PHD2
was less effective at suppressing HIF reporter gene activity,
compared with wild type protein (Percy et al. 2006).
The patient was recruited through his consultant physi-
cian, and provided written, informed consent for the
study, which was approved by the Oxfordshire Clinical
Research Ethics Committee. After baseline measurements
including spirometry, serum iron indices and arterial
blood gas sampling (Table 1), the patient was exposed to
a 10-min period of mild eucapnic hypoxia (end-tidal PO2
70 mmHg), followed by a 10-min period of moderate
eucapnic hypoxia (end-tidal PO2 50 mmHg), using a pur-
pose-built end-tidal forcing gas control system (Robbins
et al. 1982). During hypoxia, minute ventilation was mea-
sured continuously, and systolic pulmonary artery pres-
sure (SPAP) and cardiac output were estimated beat-by-
beat using non-invasive Doppler echocardiography. This
methodology has previously been used to assess a group
of three patients with Chuvash polycythemia, plus six
healthy control subjects. These results have been reported
elsewhere (Smith et al. 2006), but are reproduced in Fig-
ure 1 and Table 1, for comparison with the current case.
Spirometry revealed slightly reduced forced expiratory
volume in one second (FEV1) and forced vital capacity
(FVC) in the PHD2-deficient patient, compared with age,
Table 1. Physical characteristics and blood indices in a patient
with erythrocytosis secondary to PHD2 mutation, compared with
values from previously published studies on patients with Chuvash
polycythemia and healthy control participants (Smith et al. 2006).
Healthy control
participants
Mean  SD
(n = 6)
Chuvash
polycythemia
Mean  SD
(n = 3)
PHD2-
deficient
patient
(n = 1)
Physical characteristics
Age (year) 24  5 22  5 35
Height (cm) 173  10 174  5 175
Weight (kg) 73  11 59  10 80
Body mass index
(kg/m2)
24  2 20  5 26
Full blood count
Hemoglobin (g/L) 137  17 141  21 178
Hematocrit 0.42  0.05 0.48  0.08 0.52
Mean cell volume
(fL)
89  3 64  61 85
Serum iron studies
Iron (lmol/L) 17  4 4  11 16
Ferritin (ng/ml) 49  37 2  1 193
Transferrin (g/L) 2.6  0.5 3.8  0.31 2.2
Transferrin
saturation (%)
30  9 4  1 32
Arterial blood gases
PO2 (mmHg) 99  11 102  3 107
PCO2 (mmHg) 40  4 34  21 36
pH (mmHg) 7.38  0.02 7.41  0.021 7.45
1
Significant difference compared with control participants
(P < 0.05, Student’s t-test). Mean  SD.
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gender and height adjusted normal values (FEV 74% and
FVC 78% predicted, respectively). Similar results were
seen previously in patients with Chuvash polycythemia
(Smith et al. 2008b). As shown in Table 1, hemoglobin
and hematocrit were elevated but mean corpuscular vol-
ume and iron studies were normal. Arterial blood gas
analysis revealed a PCO2 of 36.3 mmHg with borderline
alkalosis (pH 7.45), compatible with a mild elevation of
basal pulmonary ventilation, relative to metabolism.
Figure 1 shows the ventilatory and pulmonary vascular
responses to hypoxia in the PHD2-deficient patient, com-
pared with previously reported responses in patients with
Chuvash polycythemia and in normal volunteers (Smith
et al. 2006). With regard to minute ventilation, the
patient had a normal response to mild hypoxia, but a
substantially enhanced ventilatory response to moderate
hypoxia, similar to that seen in the Chuvash patients.
With regard to pulmonary hemodynamics, the patient
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Figure 1. Changes in minute ventilation and systolic pulmonary artery pressure (SPAP) during 10 min of mild and moderate hypoxia in a
patient with PHD2 mutation (current report), compared with previously published (Smith et al. 2006) responses in normal control participants
(n = 6) and patients with Chuvash polycythemia (n = 3). End-tidal partial pressures of oxygen (PETO2) and carbon dioxide (PETCO2) were
controlled using dynamic end-tidal forcing. Symbols show mean  SEM.
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had mildly elevated baseline SPAP, intermediate between
the normal and Chuvash groups. During hypoxia, the
magnitude of the rise in SPAP in the PHD2-deficient
patient again appeared to be intermediate between the
normal response and the exaggerated response seen in
Chuvash patients.
Discussion
From a cardiopulmonary perspective, the best-character-
ized oxygen sensing mutations are those associated with
Chuvash polycythemia, in whom we have previously
described elevated basal ventilation and pulmonary artery
pressure, and dramatically enhanced ventilatory, pul-
monary vascular and cardiac sensitivity to acute hypoxia
(Smith et al. 2006, 2008b). We have also described a
small number of patients with HIF2a gain-of-function
mutations, who also have elevated basal ventilation and
pulmonary artery pressure, a moderately enhanced pul-
monary vascular sensitivity to hypoxia, but a normal ven-
tilatory sensitivity to hypoxia (Formenti et al. 2011).
Using similar methodology, we now describe an interme-
diate phenotype associated with PHD2 mutation, with
mildly elevated basal ventilation and pulmonary artery
pressure, a marked increase in the ventilatory sensitivity
to hypoxia, but only a relatively modest increase in the
pulmonary vascular sensitivity to hypoxia.
We cannot exclude some contribution from the moder-
ately raised blood viscosity to the elevation of pulmonary
artery pressure in this case. However, pulmonary hyper-
tension is reported in PHD2-deficient mice in the absence
of polycythemia (Dai et al. 2016; Kapitsinou et al. 2016),
and in a previous patient with elevated pulmonary artery
pressure and erythrocytosis secondary to HIF2a mutation,
therapeutic venesection was not associated with any
change in pulmonary artery pressure or the magnitude of
the pulmonary vascular response to hypoxia (Formenti
et al. 2011).
Several factors could contribute to the apparently
milder pulmonary vascular phenotype associated with
PHD2 mutation, compared with the Chuvash phenotype.
First, PHD2 is reported in cell culture to be of greater
importance in the regulation of HIF1a, compared with
HIF2a (Appelhoff et al. 2004), while HIF2a appears to be
primarily responsible for the pulmonary hypertension
associated with Chuvash polycythemia, at least in mice
(Hickey et al. 2010). However, despite its apparent prefer-
ence for HIF1a in cell culture, PHD2 appears nonetheless
to be an important regulator of HIF2a in vivo. Condi-
tional PHD2 inactivation was recently shown in mice to
result in pulmonary hypertension and enhanced ventila-
tory sensitivity to hypoxia (Hodson et al. 2016; Kapitsi-
nou et al. 2016). The effects of PHD2 inactivation were
dependent upon the presence of HIF2a, but were largely
unaffected by concomitant loss of HIF1a.
Second, it has also been reported in mouse models of
Chuvash polycythemia that abnormal erythrocytosis results
not only from HIF upregulation, but also from VHL-
dependent, HIF-independent activation of the JAK-STAT
signaling pathway, leading to enhanced sensitivity of ery-
throid precursor cells to erythropoietin (Russell et al.
2011). If this pathway also contributes to the pulmonary
vascular phenotype in human Chuvash polycythemia, it
may not be recapitulated in patients with PHD2 mutations.
Third, a notable difference between the previously
reported Chuvash patients and the current PHD2-defi-
cient patient is the presence of severe iron deficiency in
the former group. This is likely to reflect the greater
severity of erythropoietin dysregulation in patients with
Chuvash polycythemia, in whom frequent venesection is
required, with consequent iron deficiency. In contrast, the
current PHD2-deficient patient required less frequent
venesection, and remained iron replete. Iron deficiency
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Figure 2. Systolic pulmonary artery pressure (SPAP) breathing
room air (Normoxia) and after 10 min of hypoxia (Acute Hypoxia;
end tidal PO2 50 mmHg) in a patient with PHD2 mutation,
compared with previously published (Smith et al. 2006, 2008a)
responses in normal control participants (n = 8), patients with
Chuvash polycythemia (n = 3), healthy volunteers immediately after
prolonged hypoxia (end tidal PO2 55 mmHg for 8 h; n = 8), and
healthy volunteers immediately after infusion of the iron chelator
desferrioxamine mesylate (4 g per 70 kg over 8 h; n = 8). Symbols
show mean  SEM.
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may mimic hypoxia at a cellular level by limiting the
intracellular availability of iron, which is required as a
co-factor for the catalytic activity of the PHD proteins.
Accordingly, it has recently been reported that iron defi-
ciency in otherwise healthy individuals is associated with
enhanced pulmonary vascular responses to hypoxia (Frise
et al. 2016) and it has been suggested before that iron
deficiency may contribute to the Chuvash pulmonary vas-
cular phenotype (Sable et al. 2012). In this context, Fig-
ure 2 shows the striking similarity between the
pulmonary vascular response to hypoxia in the current
PHD2-deficient patient and the corresponding response
in healthy individuals exposed either to 8 h of hypoxia,
or to an 8-h infusion of the iron chelator desferrioxamine
(Smith et al. 2008a).
Finally, our results may have important clinical impli-
cations. In combination with previous reports of pul-
monary hypertension in patients with VHL and HIF2
mutations (Bushuev et al. 2006; Smith et al. 2006; Gale
et al. 2008; Bond et al. 2011; Formenti et al. 2011; Sar-
angi et al. 2014), our findings support the idea that
patients presenting with erythrocytosis secondary to oxy-
gen sensing mutations should be monitored for car-
diopulmonary abnormalities (Bento et al. 2014; McMullin
2016). This might be particularly important for those in
whom venesection is being considered, or in patients
likely to be exposed to hypoxia, such as through ascent to
high altitude or during air travel. In Chuvash poly-
cythemia, for example, flight-induced pulmonary hyper-
tension can develop even when baseline pulmonary artery
pressures are not elevated (Smith et al. 2013; Turner et al.
2015). Our results are also significant in the light of the
emerging role for small molecule PHD inhibitors in clini-
cal practice, for example to upregulate EPO production
in the treatment of patients with renal anemia (Brigandi
et al. 2016; Provenzano et al. 2016). Early phase clinical
trials investigating these inhibitors have now been com-
pleted. Our results raise the possibility that these agents
may produce significant alterations in cardiorespiratory
control that have not yet been widely considered.
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